^
    Back
    Association details:
    Biomarker:HR positive
    Cancer:HER2 Negative Breast Cancer
    Drug:Herceptin (trastuzumab) (HER2 inhibitor) +
    Verzenio (abemaciclib) (CDK4/6 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Clin Cancer Res
    Title:

    Overall survival and exploratory biomarker analyses of abemaciclib plus trastuzumab with or without fulvestrant vs trastuzumab plus chemotherapy in HR+, HER2+ metastatic breast cancer patients

    Published date:
    10/31/2023
    Excerpt:
    In this phase II trial, abemaciclib + trastuzumab +/- fulvestrant numerically improved median OS in women with HR+, HER2+ ABC compared to SOC chemotherapy + trastuzumab.
    Secondary therapy:
    fulvestrant
    DOI:
    10.1158/1078-0432.CCR-23-1209
    Trial ID:
    monarcHER